{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-073116","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.439279+00:00","generated_at":"2026-06-01T04:37:47.942070+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Intellia shareholders approve officer liability limitation, re-elect directors at annual meeting","bullets":["Stockholders approved amendment limiting officer liability under DGCL; 69M for, 2.9M against.","Fred Cohen and Frank Verwiel re-elected as Class II directors with 65.4M and 55.8M votes for, respectively.","Deloitte & Touche ratified as auditor for FY2024; 83.5M for, 256.7K against.","Say-on-pay proposal passed with 70.4M for, 1.5M against.","Certificate of Second Amendment filed with Delaware Secretary of State on June 12, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-073116","json":"https://secwatch.observer/filing/0000950170-24-073116.json","markdown":"https://secwatch.observer/filing/0000950170-24-073116.md","text":"https://secwatch.observer/filing/0000950170-24-073116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024073116/0000950170-24-073116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024073116/ntla-20240612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:37:47.942070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}